AstraZeneca announces positive results for phase III trial of Lynparza in advanced ovarian cancer
AstraZeneca and its collaborator MSD have announced more positive phase III trial results for Lynparza (olaparib).
The PAOLA-1 trial tested the drug in women with advanced ovarian cancer when added to the standard bevacizumab treatment, compared to using bevacizumab alone.
Those taking the two survived longer or lived without disease progression for longer than those on bevacizumab alone.
José Baselga, AstraZeneca’s executive vice president, oncology R&D, said: “The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer.
“Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive phase III trial for Lynparza as a 1st-line maintenance treatment for women with advanced ovarian cancer. We look forward to discussing the results with global health authorities as soon as possible.”
Ovarian cancer is the eighth most common cause of cancer death in women worldwide. There were nearly 300,000 new cases diagnosed in 2018 and around 185,000 deaths.
Lynparza, which is approved in 64 countries, is a first-in-class PARP inhibitor.
Earlier this month, there were encouraging phase III results for Lynparza for men with metastatic castration-resistant prostate cancer who had specific gene mutations.
Read more
Encouraging phase III trial results for AstraZeneca for lung cancer and prostate cancer drugs
AstraZeneca sales rise 12% - and busy second half of 2019 predicted
AstraZeneca and MSD share positive results for Lynparza in ovarian and pancreatic cancer trials
AstraZeneca immunotherapy for stage 3 lung cancer patients now available in England
How AstraZeneca achieved a fivefold increase in its new medicines success rate
AstraZeneca and Cancer Research UK launch joint Functional Genomics Centre in Cambridge
